SKP2 and chronic myelogenous leukemia, BCR-ABL1 positive: In the present study, we try to explore the diagnostic/prognostic impact of SKP2 gene expression for predicting treatment responses in first-line IM-treated CML patients at an early time point (3 months), which could help to refine recommendations for treatment options at the early response stage.